We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

Looking Beyond the Spike Protein for SARS-CoV-2 Vaccine Design
Industry Insight

Biotech company COVAXX is developing a COVID-19 vaccine using a multi-antigen peptide platform, which not only targets the infamous SARS-CoV-2 Spike (S) protein but also targets other parts of the virus to enhance the immune response. Technology Networks spoke with Mei Mei Hu, co-founder of COVAXX, to learn more about the vaccine platform and the preclinical data that has been obtained for UB-612.

Read More

Pushing the Boundaries of Translational Molecular Imaging
Industry Insight

Professor Ron Heeren recently embarked on a study to bring together the spatial molecular information that is provided by MALDI-MSI with the microproteomic characterization generated by LC-MS on the same tissue specimen, on a single instrument. Heeren and colleagues were successful in this feat. Their work is published in the journal Proteomics and forms the basis of this interview.

Read More

A Smarter Way To Remove Host Cell Protein Contamination From Gene Therapies
Industry Insight

In this piece, Ejvind Mørtz and Todd Stawicki explain why it’s critical that gene therapy products are free of host cell proteins and how this can be ensured in the production process, so that these next-generation drugs can fulfil their potential as one-shot cures for a range of diseases, from rare genetic conditions to cancer.

Read More

Which COVID-19 Vaccines Are in Human Clinical Trials?
Industry Insight

A hub page dedicated to bringing you the latest updates on which COVID-19 vaccines are in human clinical trials.

Read More

A Conversation With Professor Josef Penninger on the Journey to a COVID-19 Therapeutic
Industry Insight

The ACE2 receptor has garnered significant attention for the wrong reasons over recent months. Could it point towards an exit route out of this pandemic? In an interview with Technology Networks, the renowned immunologist Professor Josef Penninger explains why he thinks so, and discusses the latest clinical data obtained from testing the soluble ACE2 receptor, APN01.

Read More

Ultra-High-Throughput Proteomics To Discover New Biomarkers To Predict COVID-19 Severity
Industry Insight

In a study recently published in Cell Systems, a new ultra-high-throughput proteomics method was used to identify 27 blood biomarkers that distinguished COVID-19 patients with mild or severe responses. We spoke to Dr Markus Ralser to learn more about the study and how the method could potentially be used in the clinic to diagnose COVID-19 severity.

Read More

Exploring the Technology Behind a Blood Test for Alzheimer's Disease
Industry Insight

Technology Networks recently spoke to Quanterix's Kevin Hrusovsky to hear more about how the company's technology is being applied in the pursuit of a biomarker for Alzheimer's disease, a progressive neurodegenerative condition for which diagnosis often occurs after the onset of symptoms.

Read More

Breaking Down Barriers in Proteomic-Based Drug Discovery
Industry Insight

SomaLogic recently announced an agreement with the biopharmaceutical company Amgen that aims to advance Amgen's drug discovery and development programs through comprehensive proteomic profiling. We spoke with Roy Smythe to discover what barriers have been holding proteome analysis back, and how the collaboration with Amgen aims to change the landscape of drug discovery.

Read More

Targeting “Undruggable” Proteins by Selectively Controlling mRNA Translation
Industry Insight

Up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed a platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.

Read More

Scripps Research Spin-Off Ushers a "New Era" in Vaccinology With Platform Technology
Industry Insight

Scripps Research spin-off company Ufovax employs the single-component self-assembling protein nanoparticle (1c-SApNP®) platform technology, that was created in the laboratory of Professor Jiang Zhu, to address some of the key challenges in modern vaccine development. We spoke with Dr Colette Saccomanno to learn more.

Read More

 
Advertisement